VLX1570

VLX1570

CAT N°: 29721
Price:

54.00 45.90

VLX1570 is an inhibitor of 19S proteasomal deubiquitinases with IC50 values of 6.4 and 13 ?M for deubiquitinase activity in vitro using Ub-rhodamine and Ub-AMC, respectively, as substrates.{53378,53379} It is selective for proteasomal deubiquitinases over a panel of deubiquitinases at 20 ?M, but inhibits USP5 by greater than 50%, and over a panel of 211 kinases at 10 ?M, but inhibits Cdk4 by 77%.{53378} VLX1570 binds to and inhibits recombinant ubiquitin-specific protease 14 (USP14) and ubiquitin carboxyl-terminal hydrolase isozyme L5 (UCHL5) in vitro, and inhibits the USP14 and UCHL5 activity of purified 19S proteasomes when used at a concentration of 50 ?M.{53378,53379} It inhibits the proliferation of KMS-11, RPMI-8226, OPM-2, and OPM-2-BZR multiple myeloma cells (IC50s = 43, 74, 126, and 191 nM, respectively), as well as induces apoptosis and increases the accumulation of polyubiquitinated proteins.{53379} VLX1570 (3 mg/kg per day for 10 days) increases survival and reduces tumor growth in KMS-11-LUC2 and RPMI-8226 mouse xenograft models, respectively.

We also advise you